Filing Details
- Accession Number:
- 0001567619-22-021864
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-12-20 16:18:41
- Reporting Period:
- 2022-12-16
- Accepted Time:
- 2022-12-20 16:18:41
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1623715 | Imago Biosciences Inc. | IMGO | Pharmaceutical Preparations (2834) | 454915810 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1755509 | Michael Arenberg | C/O Imago Biosciences, Inc. 303 Twin Dolphin Drive, 6Th Floor Redwood City CA 94065 | See Remarks | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2022-12-16 | 72,645 | $15.45 | 72,645 | No | 4 | M | Direct | |
Common Stock | Disposition | 2022-12-16 | 47,750 | $35.78 | 24,895 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2022-12-16 | 72,645 | $0.00 | 72,645 | $15.45 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
30,355 | 2022-12-15 | 2032-11-07 | No | 4 | M | Direct |
Footnotes
- The transaction was executed in multiple trades in prices ranging from $35.78 to $35.785, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.